Stay up to date with the latest breaking news, analysis and commentary on Mirae Asset Sharekhan. Find live updates, exchanges, stock news, earning news and more.
Biocon Biologics subsidiary of Biocon announced the Company has secured multiple market access agreements for Yesintek (ustekinumab-kfce), its biosimilar to Stelara (ustekinumab). The market access agreements from numerous plans represent over 100+ million lives in the United States.
The Company is also finalizing formulary agreements with other commercial carriers.
At 10.06 am, Biocon was trading at Rs. 332.20, up by 4.25%, with a volume of 0.51 lakh shares on the BSE.
Q4 earnings for the Quarter ended March 31, 2025
5 May 2025, 2:37PMLatanoprostene Bunod is used to reduce intraocular pressure (IOP) in patients
30 Apr 2025, 3:38PMIndian stock markets are trading lower on an Auspicious day.
30-04-2025 09:27:54Launch of Golden Mist French Brandy in Karnataka by Allied Blenders and Distillers
28-04-2025 11:37:31Sonata Soft bags 5-yr contract worth $73 m from a US Technology, Media, and Telecom sector co
28-04-2025 09:56:51Budget 2024 Analysis
